Bristol Myers Squibb in collaboration with Johnson & Johnson today announced the decision to stop the Phase 3 Librexia ACS trial evaluating the efficacy and safety of milvexian when added to the ...

The phase 3 Librexia ACS trial evaluating the safety and efficacy of milvexian after a recent acute coronary syndrome has been discontinued.

Papillary muscle scarring (papSCAR) as detected by dark blood delayed-enhancement cardiovascular magnetic resonance (CMR) was ...

Background The epidemiology of sudden cardiac arrest (SCA) in the Mediterranean area remains unclear. The aim of this study ...

The benefit of beta-blockers after myocardial infarction in patients with a preserved left ventricular ejection fraction ...

A major analysis led by the Centro Nacional de Investigaciones Cardiovasculares (CNIC), in collaboration with international institutions, has pooled data from 17,801 myocardial infarction survivors ...

There is a bidirectional association between myocardial infarction and late-onset epilepsy, according to a recent study.

A blocked coronary artery causing an acute heart attack must be opened immediately with a stent procedure. However, if other ...

Hypereosinophilic syndrome (HES) is a heterogeneous disorder characterised by persistent, abnormal eosinophil elevation in ...

NEW ORLEANS -- Patients experiencing major heart attacks had a lower risk of serious complications if they received a single ...

Apparently, when someone has a pacemaker, there's a battery too, and they don't bother taking it out/off. They simply snip ...